Scutellarin (Flavonoid Glycoside)

Scutellarin is a flavonoid glycoside primarily extracted from Erigeron breviscapus that demonstrates anti-inflammatory and cardiovascular protective effects. It modulates inflammatory pathways including TLR4/NF-κB signaling and has been used clinically in China for stroke and myocardial infarction treatment for over 30 years.

Origin & History

Scutellarin is a flavonoid glycoside (flavone-7-O-glucuronide) primarily extracted from the Chinese herb Erigeron breviscapus (Vant.) Hand.-Mazz., and also found in Scutellaria baicalensis and Scutellaria barbata. It is isolated from these plants used in traditional Chinese medicine for cardiovascular and inflammatory conditions.

Historical & Cultural Context

Scutellarin is derived from Erigeron breviscapus, a herb used in traditional Chinese medicine for cardiovascular diseases, stroke, and inflammation. It has been used clinically for these indications for over three decades, representing a modern pharmacological extension of traditional TCM applications.

Health Benefits

• Anti-inflammatory effects: Reduces inflammatory markers (IL-1β, IL-6, TNF-α) and modulates TLR4/NF-κB pathway (preclinical evidence from mouse arthritis models, PMID: 28849116)
• Cardiovascular protection: Used clinically for stroke and myocardial infarction for over three decades (clinical evidence quality not specified in available research)
• Neuroprotective properties: Inhibits inflammatory PANoptosis in macrophages by reducing mitochondrial ROS generation (in vitro evidence, PMID: 39029229)
• Anti-cancer activity: Activates IDH1, inhibits glycolysis, and enhances tumor immunity in hepatocellular carcinoma models (preclinical evidence)
• Joint health support: Protects cartilage via aggrecan/collagen II regulation and MMP modulation in osteoarthritis models (preclinical evidence)

How It Works

Scutellarin inhibits inflammatory signaling by suppressing the TLR4/NF-κB pathway, reducing production of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. The compound demonstrates cardiovascular protection through mechanisms that support cerebral and cardiac circulation, though the precise molecular targets for these effects require further elucidation. Its anti-inflammatory activity appears to involve direct modulation of toll-like receptor signaling cascades.

Scientific Research

While scutellarin has been used clinically for over three decades for stroke, myocardial infarction, and diabetic complications, the available research lacks specific human clinical trial data with PMIDs. Current evidence primarily consists of preclinical studies including in vitro macrophage studies (PMID: 39029229) and mouse arthritis models using 20 mg/kg/day oral dosing (PMID: 28849116).

Clinical Summary

Scutellarin has been used clinically in traditional Chinese medicine for stroke and myocardial infarction treatment for over three decades, indicating established therapeutic applications. Preclinical studies in mouse arthritis models demonstrate significant anti-inflammatory effects with measurable reductions in inflammatory biomarkers. However, rigorous randomized controlled trials with Western populations are limited, and most evidence comes from traditional use patterns and animal studies. The clinical evidence base would benefit from larger-scale controlled human trials to validate therapeutic efficacy and optimal dosing protocols.

Nutritional Profile

Scutellarin is a pure bioactive flavonoid glycoside compound (4',5,6-trihydroxyflavone-7-glucuronide), not a whole food ingredient, and therefore does not contain macronutrients (protein, fat, carbohydrate), dietary fiber, or conventional micronutrients in nutritional terms. Molecular weight: 462.37 g/mol. As a glycoside, it consists of a scutellarein aglycone backbone linked to a glucuronic acid moiety at the 7-position. Primary bioactive compound: scutellarin itself at 100% of the isolate when in standardized extract form. When derived from Erigeron breviscapus (fleabane herb), standardized pharmaceutical-grade extracts typically contain 85–98% scutellarin purity. Bioavailability is notably poor via oral route: absolute oral bioavailability estimated at approximately 2.1–7.4% in rodent models due to extensive first-pass metabolism and poor intestinal absorption. Intestinal bacteria hydrolyze scutellarin to its aglycone scutellarein, which is then partially reabsorbed. Peak plasma concentration (Cmax) reached approximately 1–2 hours post oral administration. Intravenous formulations (as used clinically in China, e.g., 50 mg scutellarin injection) bypass absorption limitations and achieve significantly higher bioavailability. Protein binding: approximately 85–90% bound to plasma proteins. The compound is lipophilic enough to cross the blood-brain barrier, supporting its neuroprotective applications. No vitamins, dietary minerals, or fiber content applicable to this isolated compound.

Preparation & Dosage

No clinically studied human dosage ranges are available in the research. Preclinical mouse studies used 20 mg/kg/day orally for 2 weeks. Human dosing information and standardization details are not specified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ginkgo biloba, Curcumin, Resveratrol, Quercetin, Green tea extract

Safety & Interactions

Safety data for scutellarin supplementation is limited, with most information derived from traditional use patterns rather than systematic safety studies. Potential interactions with anticoagulant medications may exist given its cardiovascular effects, though specific drug interactions have not been well-documented. Pregnancy and breastfeeding safety has not been established through clinical research. Individuals with bleeding disorders or those scheduled for surgery should exercise caution due to potential effects on circulation and blood flow.